UBX Stock Overview
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Unity Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.49 |
| 52 Week High | US$3.82 |
| 52 Week Low | US$1.47 |
| Beta | 0.87 |
| 1 Month Change | -5.10% |
| 3 Month Change | -13.37% |
| 1 Year Change | -26.96% |
| 3 Year Change | -97.12% |
| 5 Year Change | -98.19% |
| Change since IPO | -99.11% |
Recent News & Updates
Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation
Mar 05
Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky
Nov 18Recent updates
Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation
Mar 05Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky
Nov 18UNITY Biotechnology falls 7% on reverse stock split
Oct 19Unity Biotechnology cuts stock sales agreement in half to $25M
Aug 19Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M
Aug 12A Look At Unity's UBX1325 Phase 1 Results
Jul 26Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently
Dec 22A Look Inside Unity Bio's Transition To An Ophthalmology Company
Nov 27Shareholder Returns
| UBX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.0% | -2.5% | -3.2% |
| 1Y | -27.0% | -3.7% | 19.3% |
Return vs Industry: UBX underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: UBX underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| UBX volatility | |
|---|---|
| UBX Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: UBX's share price has been volatile over the past 3 months.
Volatility Over Time: UBX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 19 | Anirvan Ghosh | unitybiotechnology.com |
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.
Unity Biotechnology, Inc. Fundamentals Summary
| UBX fundamental statistics | |
|---|---|
| Market cap | US$24.84m |
| Earnings (TTM) | -US$39.86m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs UBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UBX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$19.70m |
| Gross Profit | -US$19.70m |
| Other Expenses | US$20.16m |
| Earnings | -US$39.86m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did UBX perform over the long term?
See historical performance and comparison